Business
Argo Biopharma Announces Multi-Asset License and Option Agreements with Novartis for Novel Molecules for Cardiovascular Diseases
Argo Biopharmaceutical Co., Ltd. (Argo Biopharma, the Company), a clinical-stage biotechnology company focused on developing next-generation siRNA therapeutics, today announced that it has entered into an additional strategic collaboration with Novartis (NYSE: NVS) for multiple cardiovascular assets in Argo's pipeline. The new agreements are in addition to the existing collaboration between the two companies and comprise their third transaction including assets from Argo's pipeline.
About this update from Novartis Ag
[{"type":"list","items":[{"val":[{"type":"text","content":"Agreement to explore Argo's Phase 2 ANGPTL3 in a combination trial in dyslipidemia with an option to license second-generation molecules in the pipeline","length":156,"tagName":"p"}]},{"val":[{"type":"text","content":"License to an additional Argo siRNA candidate currently in IND-enabling studies","length":79,"tagName":"p"}]},{"val":[{"type":"text","content":"Argo will receive an upfront payment of $160 million, an option for Profit & Loss split across multiple geographies and potential near-term equity; Argo is also eligible to receive option payment, development, sales milestones and royalties on commercial sales","length":264,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":499,"olType":false},{"type":"text","content":"SHANGHAI and BOSTON, Sept. 3, 2025 /PRNewswire/ -- Argo Biopharmaceutical Co., Ltd. (Argo Biopharma, the Company), a clinical-stage biotechnology company focused on developing next-generation siRNA therapeutics, today announced that it has entered into an additional strategic collaboration with Novartis (NYSE: NVS) for multiple cardiovascular assets in Argo's pipeline. The new agreements are in addition to the existing collaboration between the two companies and comprise their third transaction including assets from Argo's pipeline.","length":546,"tagName":"p"},{"type":"text","content":""We are thrilled to deepen our collaboration with Novartis, a global leader in Cardiovascular, Renal and Metabolic areas," said Dr. Dongxu Shu, Co-Founder, Chairman of the Board, and CEO of Argo Biopharma. "This new collaboration further supports the innovation engine Argo has built to deliver best-in-class siRNA therapeutics while building a top-tier clinical development team across multiple geographies. Argo's ambition is to become a global biotech, and corporate development activities are an important component to expand the reach of our hepatic and ex-hepatic siRNA therapeutics."","length":620,"tagName":"p"},{"type":"text","content":""Long-acting siRNAs which are designed to deeply and durably target disease-causing proteins represent an important paradigm shift in prevention and treatment of cardiovascular diseases. We are excited to build on our work with Argo through these new agreements, which include additional molecules...